drugset / Trial / NCT00821964

Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer

NCT00821964

NaSingle-groupOpen-labelTreatment

Summary

This phase II trial is studying the side effects of giving topical imiquimod together with Abraxane (paclitaxel albumin-stabilized nanoparticle formulation) to see how well it works in treating patients with advanced breast cancer. Biological therapies, such as imiquimod, may stimulate the immune system to kill tumor cells. Drugs used in chemotherapy, such as Abraxane, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving imiquimod together with Abraxane may kill more tumor cells.

Timeline

Start
2008-12
Primary completion
2012-11
Completion
2012-11-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Imiquimod Other / unclassified 5 % Topical
Subject Paclitaxel Small molecule 100 mg/m2 Intravenous